Zydus Lifesciences has announced the launch of its companion diagnostics portfolio with the introduction of Diasens and GlucoLive, continuous glucose monitoring (CGM) devices designed for diabetes management.
The company stated that the devices combine artificial intelligence-based insights with remote care capabilities. The CGM system is designed to monitor glucose levels with an integrated AI layer that provides analytics and enables a closed-loop care ecosystem connecting patients, caregivers and clinicians in real time.
Zydus has partnered with Digicare Health Solutions Private Limited (TatvaCare) to enable patient access to its integrated care ecosystem GoodFlip. According to the company, the mobile application provides AI-powered report analysis, diet and exercise coaching, doctor consultations, diagnostic laboratory booking and a medical record vault within a single platform.
Speaking on the launch, Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said, “The launch of DiasensTM and GlucoLiveTM strengthen our companion diagnostics portfolio for chronic disease management. Focused on patient-centric convenience and better quality of life, these CGMs powered by AI technology, will give patients real-time access to key glycaemic data on their mobile devices, simplifying monitoring and control. The convergence of science, innovation, health and technology is critical for patients managing chronic diseases like diabetes, CKD, or organ transplant – offering a quick, reliable, and safe glucose monitoring solution with utmost convenience.”
India has more than 101 million adults living with diabetes, the second-highest burden globally, according to the Indian Council of Medical Research INDIAB study published in The Lancet Diabetes & Endocrinology. The study also reported that 136 million individuals are in the pre-diabetic stage. Diabetes is the leading cause of Chronic Kidney Disease in India, with 25–40 per cent of CKD patients having a diabetes history. The company stated that around 200,000 patients require kidney transplants and 25,000 require liver transplants each year, with many developing diabetes due to immunosuppressive therapies.
The company noted that glucose monitoring in India remains episodic, with patients relying on finger-prick tests or laboratory HbA1c tests conducted every three to six months. Existing CGM devices in the market rely on near field communication technology, requiring patients to manually scan sensors to retrieve readings.
Diasens and GlucoLive will automatically stream glucose readings to a patient’s smartphone every three minutes without manual scanning, according to the company. The system captures data continuously, including overnight readings and emergency situations. Through TatvaCare’s GoodFlip application, AI analytics will identify trends, flag hypo- and hyperglycaemic episodes, link fluctuations to food intake and activity, and generate insights for users. The company stated that a clinician dashboard will support remote monitoring, early intervention and treatment adjustments based on data.